Introduction
Prostate cancer is the most frequently diagnosed non-skin cancer in men in the United States (US), and the second leading cause of male cancer deaths(1). In addition, alcohol consumption accounts for a substantial amount of deaths worldwide, with cancer contributing to this burden. Mounting evidence supports alcohol as a risk factor for female breast, colorectal, oral cavity, pharynx, larynx, esophagus and liver cancers (2) , but there is little agreement concerning its effect on prostate cancer risk.
Individual studies have found mixed results regarding the effect of alcohol consumption and overall prostate cancer risk; including null (3) (4) (5) (6) , inverse (7, 8) and positive associations (9, 10) . Results of a recent meta-analysis found a statistically significant dose-response relationship between the quantity of alcohol consumption and overall prostate cancer risk (11) . Another study found that heavier drinking was associated with increased risk of high-grade disease, but had no association with low-grade prostate cancer risk (12) . Finally, one case-control study found that current alcohol intake was not associated with prostate cancer risk but that cumulative lifetime intake increased significantly the risk of both aggressive and nonaggressive prostate cancer (13) , suggesting that alcohol exposure earlier in life may be important.
Using data from a prostate biopsy cohort at the Durham Veteran Affairs Medical Center, our objective was to test the association between early-life alcohol consumption and prostate cancer diagnosis. In addition, we aimed to determine if early-life alcohol consumption was associated with tumor aggressiveness at diagnosis. Given that carcinogenic exposures during prostate development might affect prostate cancer risk later in life (14) , we hypothesized that heavier alcohol intake earlier in life would be associated with increased odds of prostate cancer diagnosis at biopsy, particularly highgrade disease.
Materials and Methods

Study Design
Men undergoing prostate biopsy for an elevated PSA and/or abnormal digital rectal examination (DRE) at the Durham Veterans Affairs Medical Center between January 2007 and January 2018 were recruited to participate in an ongoing biopsy cohort study. Methods for identification and accrual of participants have been described previously (15) . Men were at least 18 years of age, had a PSA test within 12 months prior to enrollment, and had no history of prostate cancer. Of the 1595 eligible men who underwent biopsy, 1,221 (77%) consented to participate. Of these, we excluded 12 patients missing biopsy results, 528 patients who did not complete or partially completed the study questionnaire, and 31 missing key covariates, resulting in a study cohort of 650 patients. Men missing study questionnaires were slightly younger, less likely to be white, had higher PSA at biopsy, and were more likely to be diagnosed with overall prostate cancer but equally likely to be diagnosed with high-grade prostate cancer (data not shown). The study was approved by the Institutional Review Board at Durham Veterans Affairs Medical Center and all patients provided written consent.
Data collection
Patients completed a questionnaire, including demographic, medical and lifestyle characteristics.
Alcohol intake was assessed by a question that asked "At each age, what is the average number of drinks that you consume(d) weekly?" In response to this question, men indicated the average number of alcoholic beverages consumed per week (0, <1, 1, 2-3, 4-6, 7-10, 11-15, 16-20, >20) during each decade of their life (age 15-19, 20-29, 30-39, etc.) . Type of beverage and serving size was not indicated. Cumulative lifetime alcohol consumption (i.e. the total number of drinks consumed over the lifetime prior to prostate cancer diagnosis), was calculated by summing the number of drinks/week over each decade of life, which was categorized into tertiles (13 (16) . All questionnaires were self-administered and typically filled out shortly after the biopsy and returned by mail. Anthropometric measurements (measured weight and height, used to calculate body mass index (BMI)), DRE findings, prostate volume and PSA level were abstracted from urology clinic notes from either the visit at which biopsy was performed, or the most recent visit prior to biopsy.
Outcome ascertainment
Biopsy tissue was assessed by a pathologist per standard of care and prostate cancer grade was abstracted from the resulting pathology report. Grade was assigned using Epstein's five grade group system where low-grade disease was defined as grade group (GG) 1-2 (Gleason score ≤3+4) and high-grade prostate cancer as GG 3-5 (Gleason score ≥4+3) (17) .
Statistical Methods
Patient characteristics were summarized by alcohol consumption at age 15-19 and differences were tested using Kruskal-Wallis tests for continuous variables and chi-squared test for categorical variables.
Logistic regression was used to test the association between alcohol consumption and overall prostate cancer diagnosis at biopsy. Multinomial logistic regression was used to test the association between alcohol consumption, low-grade and high-grade prostate cancer diagnosis. The primary exposure was early-life alcohol consumption, measured by the average number of alcoholic drinks consumed per week at age [15] [16] [17] [18] [19] . We also examined alcohol intake at age 20-29, and age [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . In addition, we tested current alcohol consumption at the time of biopsy. For these exposures, the number of drinks per week was categorized as 0, 1-6, and ≥7, in line with previous studies (18, 19) .
Finally, we examined tertiles of cumulative lifetime alcohol consumption.
We fit age-adjusted models and multivariable models adjusted for age, race, DRE (suspicious vs. normal), prostate volume (log-transformed), PSA at biopsy (log-transformed), year of biopsy, smoking pack years (log-transformed), previous prostate biopsy (yes vs. no), and BMI (log-transformed). For analyses of alcohol intake across different decades, models examining past alcohol consumption were additionally adjusted for current alcohol consumption (0, 1-7, ≥7 drinks per week) and models examining current alcohol consumption were adjusted for past alcohol consumption (yes vs. no). We also repeated our analysis of the association between early-life alcohol intake and prostate cancer without adjusting for current alcohol intake, and vice versa. P-values for trend were calculated by assigning the median number of alcoholic drinks among patients in each category to that category and treating it as a continuous variable. For example, for analyses of alcohol intake across different decades, median drinks per week in the ≥7 drinks per week category was 7-10 for ages 15-19, so all patients were assigned a value of 8.5 (median value of 7-10 category) for the trend analysis.
We examined whether associations between alcohol consumption and prostate cancer differed by race (white vs. non-white) by including a cross product term in the multivariable model and testing its significance using a Wald test.
All statistical tests were two-sided, and p values<0.05 were considered statistically significant.
Statistical analyses were performed using SAS v9.4 (SAS Institute, Inc.; Cary, NC).
Results
Patient characteristics
Median (IQR) age at biopsy in our cohort was 64 (60-68) and 47% of patients were white (Table 1) .
Median (IQR) PSA was 5.7 ng/ml (4.5-7.9 ng/ml). During ages 15-19, there were 317 (49%) men who reported not drinking, 279 (43%) men who reported drinking 1-6 drinks per week, and 54 (8%) who reported drinking ≥7 drinks per week. Men who reported ≥7 drinks per week at ages 15-19 had higher smoking pack years (p<0.001), but otherwise characteristics were balanced among groups.
Alcohol consumption and overall prostate cancer
There were 325 of 650 men diagnosed with prostate cancer, 238 with grade group 1-2 and 88 with grade group 3-5. There was no association between alcohol intake at ages 15-19 and odds of overall prostate cancer diagnosis, on either age-adjusted or multivariable analysis (p-trend=0.57 and p-trend=0.76, respectively; Table 2 ). On age-adjusted analysis, both 1-6 drinks per week at ages 20-29 and 1-6 and ≥7 drinks per week at ages 30-39 were associated with increased odds of prostate cancer diagnosis, although the trends across increasing categories of alcohol intake were not statistically significant (Table 2 ). This association held for 1-6 drinks per week at ages 30-39 (OR 1.64, 95% CI 1.02-2.63), but was attenuated and no longer significant for ≥7 drinks per week after adjusting for demographic and prostate characteristics in multivariable analysis.
Alcohol consumption, low-grade and high-grade prostate cancer
Like our analysis of overall prostate cancer, we found no association between alcohol intake at ages 15-19 and odds of low-grade prostate cancer (Table 3 ). Neither did we find any consistent associations between alcohol intake during other decades and low-grade prostate cancer diagnosis.
In contrast, on both age-adjusted and multivariable analysis, consumption of ≥7 drinks per week at ages 15-19 was significantly associated with an increased odds of high-grade prostate cancer diagnosis (multivariable OR 3.21, 95%CI 1.22-8.41), with a significant trend across categories of increasing alcohol intake (p-trend=0.020). We observed similar estimates for alcohol intake at ages 20-29 (multivariable OR 3.14, 95%CI 1.14-8.65, p-trend=0.034), and ages 30-39 (multivariable OR 3.09, 95%CI 1.20-8.00, p-trend=0.019). In contrast, current alcohol consumption was not significantly associated with high-grade prostate cancer diagnosis (Table 3) , with similarly null findings when models were not adjusted for past alcohol consumption (data not shown).
There were no differences in associations between alcohol consumption and prostate cancer diagnosis between white and non-white men (data not shown). Our findings were similar when models for earlier-life alcohol intake were not adjusted for current alcohol consumption ( Supplementary Table 1 ).
Cumulative lifetime alcohol consumption and prostate cancer
On age-adjusted and multivariable analysis, the middle tertile of cumulative lifetime alcohol intake was associated with moderately increased odds of overall and low-grade prostate cancer diagnosis, though trends across increasing tertiles were not statistically significant (Table 4 ). Consistent with our findings for earlier-life alcohol intake, we found that men in the upper tertile of cumulative lifetime alcohol intake had significantly increased odds of high-grade prostate cancer diagnosis, relative to those in the lowest tertile (multivariable OR 3.74; 95% CI 1.70-8.25; Table 4 ). There was a significant trend across increasing tertiles of cumulative lifetime alcohol intake in association with high-grade prostate cancer diagnosis (p<0.001).
Discussion
Both clinical and epidemiological evidence suggests that prostate carcinogenesis may span decades (20) . The prostate undergoes significant growth and maturation during puberty, so presumably, during this period it might be particularly susceptible to carcinogenic exposures. As such, consideration of early-life exposures may be important for understanding prostate cancer etiology (14) . To address this, we analyzed the association between early-life alcohol exposure and high-grade prostate cancer diagnosis among men undergoing a prostate biopsy at the Durham Veterans Affairs Medical Center. We found that men with a history of heavier alcohol exposure earlier in life were more likely to be diagnosed with high-grade prostate cancer at biopsy, compared to men with no early-life alcohol exposure. We also found that higher cumulative lifetime alcohol intake was associated with increased odds of high-grade disease. In contrast, we found no association between current drinking patterns and overall or high-grade prostate cancer diagnosis. Though additional studies are needed, these data suggest that heavier drinking patterns earlier in life may be associated with high-grade prostate cancer.
While few studies have focused on early-life alcohol consumption, multiple studies have examined the association between current alcohol consumption and prostate cancer risk, though findings are contradictory. Two meta-analyses found no association between alcohol consumption and risk of prostate cancer (3, 4) , while the most recent meta-analysis reported a modest yet significant doseresponse relationship between increasing alcohol intake and overall prostate cancer risk (11) .
Moreover, a secondary analysis of the ProtecT trial by Zuccolo et al., showed higher risk of highgrade disease for heavy drinkers, and no association of alcohol with low-grade disease (12) . Similarly, secondary analyses of the Prostate Cancer Prevention (PCPT) and REDUCE trials also showed positive associations between alcohol intake and risk of high-grade prostate cancer, though associations were significant only in men randomized to 5-alpha reductase inhibitors (5-ARIs) (18, 21) .
Together, these studies suggest that heavier alcohol intake may be more strongly related to highgrade than overall prostate cancer risk.
Several studies have investigated lifetime alcohol exposure and prostate cancer risk. A Canadian population-based case-control study showed a weak positive association between high alcohol intake over the lifetime and prostate cancer risk (22) . In another Canadian population-based case-control study, McGregor et al., showed that current alcohol intake was not associated with prostate cancer risk but that lifetime intake was associated with significantly increased risk of both low-grade and high-grade prostate cancer (13) . Breslow (26) . A study in rats showed that prostate cytosolic xanthine oxidase can bioactivate ethanol to acetaldehyde and free radicals (27) . It has been shown in cell culture that acetaldehyde induces point mutations, sister chromatid exchanges and gross chromosomal aberrations(28-30). Finally, alcohol can act as an endocrine disruptor by altering circulating levels of sex hormone-binding globulin thereby affecting total and free testosterone concentrations (31, 32) . How this may affect prostate cancer risk is unclear, given mixed evidence for a role of circulating sex hormone levels in prostate cancer (33) (34) (35) .
Our study has some limitations. First, our study may be subject to recall bias as alcohol intake was based on questionnaires completed after biopsy. However, given that alcohol is not an established risk factor for prostate cancer, any bias that occurred due to exposure misclassification would likely have been non-differential with regard to prostate cancer diagnosis, likely bringing associations towards the null. Second, 39% of men participating in this cohort were excluded from the present analysis due to missing questionnaire data, creating a potential selection bias. The excluded men tended to be younger and African American, with higher PSA at biopsy and a higher likelihood of being diagnosed with prostate cancer overall, though they were equally likely to be diagnosed with high-grade disease, and were otherwise similar to men who completed study questionnaires. How this potential selection bias may have affected our results is unknown. Third, we ascertained prostate cancer status based on biopsy outcomes and it is well known that some men with a negative biopsy still harbor prostate cancer. However, other studies have shown that the rate of misclassification in men with repeat biopsy is low (36) and therefore this is unlikely to substantially change our results.
Fourth, our reference group of non-drinkers in later decades contained past drinkers, though this would likely bias our estimates towards the null. Our analysis of cumulative lifetime intake includes alcohol intake across all decades of life and circumvents this limitation of studying specific decades of alcohol exposure. However, given that the vast majority of men reporting heavier alcohol intake at ages 15-19 were also in the upper tertile of cumulative lifetime alcohol intake, we were unable to definitively separate the potential effects of early-life exposure from cumulative lifetime exposure to alcohol in this study. Finally, our study was limited because our participant population had relatively few heavy drinkers and we did not have access to information about binge drinking patterns or beverage-specific effects. In addition, our study population was comprised of veterans, who may have unique early drinking patterns that may not be generalizable to the general population. Despite these limitations, our study benefited from alcohol questionnaires that spanned all decades of life, enabling testing of potential windows of susceptibility to alcohol exposure in the context of equal access to care. Finally, our study population was strong in diversity as 54% of participants were non-white.
In the present analysis among veterans undergoing prostate biopsy, we found a significant positive association between heavier alcohol exposure between the ages of 15 -39 and diagnosis of highgrade prostate cancer at time of biopsy, while current alcohol intake was unrelated to prostate cancer diagnosis. We also found a positive association between higher cumulative lifetime alcohol intake and high-grade prostate cancer diagnosis. These results suggest that early-life alcohol exposure and cumulative lifetime intake may be important variables to consider when analyzing prostate cancer risk. Further studies should explore early-life exposure to alcohol to validate these results. 
